CMS Approves Add-on Payment for Lutonix® Drug-Coated Balloon for Inpatient Use
August 03 2015 - 07:00AM
Business Wire
C. R. Bard, Inc. (NYSE:BCR) today announced that the U.S.
Centers for Medicare and Medicaid Services (CMS) has approved a new
technology add-on payment for the Lutonix® Drug-Coated Balloon
(DCB) under the Medicare hospital inpatient prospective payment
system. The purpose of the reimbursement is to help cover
additional cost to U.S. hospitals for treating Medicare
beneficiaries with the Lutonix® DCB in the inpatient setting. CMS
determined the amount of the add-on payment to be a maximum of
$1,036 when DCBs are used for inpatient peripheral procedures and
the total device costs exceed the allowance for existing DRG
reimbursement. The add-on payment is effective October 1, 2015.
The Lutonix® 035 DCB—the first FDA-approved DCB— is an
angioplasty balloon coated with a therapeutic dose of the drug
paclitaxel, and also utilizes standard mechanical dilatation of the
vessel to restore blood flow for patients with peripheral arterial
disease (PAD) in the femoropopliteal arteries.
Timothy M. Ring, chairman and chief executive officer,
commented, “After providing reimbursement in the outpatient setting
earlier this year, CMS has now provided additional reimbursement
for the Lutonix® DCB in the inpatient setting, which demonstrates
the benefit to patients from this breakthrough technology.”
C. R. Bard, Inc. (www.crbard.com),
headquartered in Murray Hill, N.J., is a leading multinational
developer, manufacturer and marketer of innovative, life-enhancing
medical technologies in the fields of vascular, urology, oncology
and surgical specialty products.
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current expectations, the
accuracy of which is necessarily subject to risks and
uncertainties. These statements are not historical in nature and
use words such as “anticipate”, “estimate”, “expect”, “project”,
“intend”, “forecast”, “plan”, “believe”, and other words of similar
meaning in connection with any discussion of future operating or
financial performance. Many factors may cause actual results to
differ materially from anticipated results including product
developments, sales efforts, income tax matters, the outcomes of
contingencies such as legal proceedings, and other economic,
business, competitive and regulatory factors. The company
undertakes no obligation to update its forward-looking statements.
Please refer to the Cautionary Statement Regarding Forward-Looking
Information in our June 30, 2015 Form 10-Q for more detailed
information about these and other factors that may cause actual
results to differ materially from those expressed or implied.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150803005392/en/
C. R. Bard, Inc.Investor Relations:Todd W.
Garner, 908-277-8065Vice President, Investor
RelationsorMedia Relations:Scott T. Lowry,
908-277-8365Vice President and Treasurer
Bard C R (NYSE:BCR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bard C R (NYSE:BCR)
Historical Stock Chart
From Mar 2023 to Mar 2024